Orano Med
About Orano Med
Orano Med is an Orano subsidiary created in 2009 to develop innovative therapies to fight cancer.
Nuclear Medicine
Learn more about nuclear medicine and targeted alpha therapy (TAT) with lead-212, and about our ongoing research.
Pipeline
Orano Med is always looking for new opportunities to further expand its pipeline.
News & Materials
Read about the latest news and events, watch a video, or download our brochure.
Macrocyclics
Macrocyclics, an Orano Med company, is the global leader in chelating agent technologies for medicine.
Latest News
08/01/2018
Cellectar and Orano Med Announce Collaboration to Develop New Phospholipid Drug Conjugate
Read more
01/10/2018
RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedix(TM), a Targeted Alpha Therapy for patients with neuroendocrine tumors
Read more 06/22/2017
